COMMUNIQUÉS West-GlobeNewswire

Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
06/06/2019
BLA Submission Expected First Quarter 2020 CARMIEL, Israel, June 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), or Protalix, and Chiesi Farmaceutici S.p.A, an international [...]
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
06/06/2019
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug- [...]
Athenex Provides an Update on its Chongqing API Plant
06/06/2019
BUFFALO, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)
06/06/2019
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage [...]
Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
06/06/2019
─ Scheduled to Meet with FDA to Design Proof-of-Concept Study in Suicidality-PTSD ─ Appoints Warren W. Wasiewski, MD as Chief Scientific Officer ─ Seelos to Webcast Presentation at the Jefferies 2019 Healthcare [...]
Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
06/06/2019
NEW HAVEN, Conn., June 06, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief [...]
Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis
06/06/2019
BUFFALO, N.Y. and TAIPEI, Taiwan, June 06, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for [...]
Bavarian Nordic A/S - Articles of Association
06/06/2019
Updated Articles of Association for Bavarian Nordic A/S Attachment Bavarian Nordic - Articles of Association
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
06/06/2019
COPENHAGEN, Denmark, June 6, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 100,000 as a consequence of employees’ exercise of [...]
Articles of Association for NeuroSearch A/S
06/06/2019
Articles of Association as of 29.04.2019 enslosed. Attachment NeuroSearch - Vedtægter (UK) - AGM 2019
Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes
06/06/2019
Conference call scheduled for Thursday, June 6, 2019 at 8:00 AM EDT/1:00 PM BST/2:00 PM CET NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company [...]
Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion
06/06/2019
First home-use trial of the iLet Bionic Pancreas System using pre-filled cartridges of dasiglucagon compatible with iLet has been successfully completed The preliminary study results reveal superior blood glucose [...]
Kiadis Pharma completes acquisition of CytoSen Therapeutics, Inc.
06/06/2019
Amsterdam, The Netherlands, June 6, 2019 - Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces that it has closed the [...]
Tecan to hold its 2019 Capital Markets Day
06/06/2019
Männedorf, Switzerland, June 6, 2019 – The Tecan Group (SIX Swiss Exchange: TECN) announced that it will be holding its Capital Markets Day today, Thursday June 6, 2019. The day will begin with presentations detailing [...]
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
06/06/2019
Data show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated kidneys last 10 years, [...]
COSTAS Inc. (CSSI) Acquires Medical Nanotechnology Company, Appoints New Management and Board Members
06/06/2019
LAS VEGAS, June 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – COSTAS,Inc. (OTC: CSSI), announces its acquisition of Atlas Nanotech (formerly known as Nano Creaciones SAPI de CV) in an all-stock transaction that marks [...]
VALNEVA annonce la mise à disposition des documents préparatoires à l'Assemblée d'actionnaires
06/06/2019
Valneva annonce la mise à disposition des documents préparatoires à l'Assemblée d'actionnaires Saint-Herblain (France), 6 juin 2019 - Les actionnaires de la société Valneva SE (ci-après "Valneva" ou "la Société") sont [...]
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
06/06/2019
INNATE PHARMA ENROLLS FIRST PATIENT IN IPH4102 TELLOMAK PHASE II STUDY TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma The TELLOMAK trial design and preclinical [...]
Innate Pharma a recruté le premier patient dans TELLOMAK l’étude de Phase II d’IPH4102
06/06/2019
INNATE PHARMA A RECRUTÉ LE PREMIER PATIENT DANS TELLOMAK L’ÉTUDE DE PHASE II D’IPH4102 TELLOMAK est une étude de Phase II visant à évaluer l’efficacité d’IPH4102 dans différents sous-types de lymphomes des cellules T Le [...]

Pages